Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2024 - Mental Daily. All Rights Reserved.
Clinical

Targeting the histamine H3 receptor may slow down early-stage Huntington’s disease

Staff Writer
Staff Writer 5 years ago
Updated 2020/06/09 at 11:53 PM
Share
SHARE

As published in the peer-reviewed journal eLife, a team of researchers from Spain found a potential new avenue for treating early-stage Huntington’s disease (HD).

According to the study, targeting the histamine H3 receptor may aid in inhibiting imbalances in dopamine signaling that result in symptoms associated with the genetic disorder.

“Because dopamine receptors are found in many normal cells throughout the central nervous system, we proposed that targeting dopamine signaling through the histamine receptor might be a more effective strategy to slow the progression of Huntington’s disease,” said David Moreno-Delgado, the study’s lead author.

In their examination of an HD mouse striatal cell model and organotypic brain slices, researchers determined that the dopamine D1 receptors implicated in the neuronal degeneration and brain cell death are mitigated by a histamine H3 receptor antagonist.

“We demonstrate that the D1R-H3R heteromer is expressed in HD mice at early but not late stages of HD, correlating with HD progression,” the co-authors explained in their findings. “In accordance, we found this target expressed in human control subjects and low-grade HD patients. Finally, treatment of HD mice with an H3R antagonist prevented cognitive and motor learning deficits and the loss of heteromer expression.”

As detailed in their findings, the Spanish research team concluded that the D1R – H3R heteromers are detrimental in dopamine signaling and may be a potential avenue for the development of treatment against Huntington’s disease.

Photo: iStock

You Might Also Like

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

Dementia risk factors differ by ethnicity, according to new research

Researchers investigate how endocannabinoids regulate the brain’s stress response

Study shows the risk of eating disorders may be lower among vegans

TAGGED: antihistamines, H3 receptor, huntington's disease
Staff Writer June 9, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article How eye scanning technology could detect and track biological aging
Next Article #BlackLivesMatter reached prodigious spread on Twitter, study shows

Recommended

Clinical

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

1 Min Read
Clinical

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

2 Min Read
Clinical

Dementia risk factors differ by ethnicity, according to new research

2 Min Read
Clinical

Researchers investigate how endocannabinoids regulate the brain’s stress response

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
  • Mental Health
Follow US

© 2024 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?